Two N.Y. HIEs align

The Adirondack Regional Community Health Information Exchange (ARCHIE) is joining forces with the Health Information Xchange of New York (HIXNY).

ARCHIE was founded by Adirondack Medicine, an independent physicians association and Glens Falls Hospital in Glens Falls, N.Y. The staff members at ARCHIE have joined the HIXNY staff.

"There was unanimity among the boards of both organizations to merge operations so the region has one operational platform related to the adoption of health IT by the provider community," said John A. Collins, MD, chief medical officer and executive vice president of Northeast Health in Troy, N.Y., and chair of HIXNY. "We are confident that the merger will result in a seamless transition and are pleased the ARCHIE staff will be joining HIXNY to enhance the operations of the health information exchange for our region."

"The ARCHIE board of directors is pleased to be joining forces with HIXNY in providing IT services that benefit patients, their doctors and health plans," said Daniel M. Chernoff, MD, PhD, and chair of ARCHIE. During and after a transitional integration period, participants in the ARCHIE data exchange will see services currently provided by ARCHIE, including patient-controlled access to health records and other services provided by the HIXNY data exchange.

ARCHIE will have a seat on HIXNY’s board of directors with the ARCHIE representative still to be determined. Similar to HIXNY, ARCHIE provides safe and secure patient data shared by providers. The data includes patient demographics, lab results, radiology and other transcribed reports, medications and allergy information.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.